Can Trump derail the 2020 economic upturn?

Capital markets have yet to enter into an early festive spirit. The first week of December made for a bad start in risk assets. As we have written before, expectations of future US-China trade relations are vital to market sentiment – and this week we saw a blow in that regard. President Trump indicated that a trade deal between the world’s two largest economies might have to wait until after the presidential election (November 2020). Markets on the other hand (when judged by equity valuation levels vs. actual profit growth) have effectively priced in a deal in the next few weeks or months.

That disappointment will sting, given the current economic backdrop. We wrote last week that markets appear to be ‘frontrunning’ the economy by pricing in a more imminent recovery from the global economic slowdown than  the economic data flow currently suggests. Equity valuations have risen close to where they were during the heady days of late 2017. Sure enough, stock markets around the globe fell 2-3% at the beginning of this week – testament to the fact that investors are feeling a little nervous about their optimism.

Tatton Asset Management PLC (LON:TAM) offers a range of services to directly authorised financial advisers in the United Kingdom. The Company provides on-platform portfolio management, regulatory, compliance, and business consulting services. 

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Tatton Asset Management Plc

    More articles like this

    boohoo Plc

    boohoo group total group sales +61% since FY2020

    boohoo group plc (LON:BOO) have today published final results for the year ended 28th February 2022. Investing for the future ·    Significantly increased market share in the UK and US since FY2020. Total group sales +61% since FY2020 ·    Extended

    Fintel plc

    Fintel Plc appoint Phil Smith as Non-Executive Director

    Fintel plc (LON: FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has announced the appointment of Phil Smith as Independent Non-Executive Director with immediate effect. Following a robust process led

    Pendragon plc

    Pendragon underlying Profit before Tax of £18.7m, up 73.1%

    Pendragon plc (LON:PDG) has announced its interim management statement. This Interim Management Statement covers the period from 1 January 2022 to 31 March 2022.  Unless otherwise stated, figures quoted in this statement are for the three

    SpaceandPeople returns to profit

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued full

    SpaceandPeople back into profit and positive earnings per share

    SpaceandPeople plc (LON:SAL) the retail, promotional and brand experience specialist, has announced its final results for the year ended 31 December 2021.   Financial Highlights ·       Revenue of £4.0 million (2020: £2.8 million and 2019: £7.7 million) ·       Operating profit of

    tinyBuild plc

    tinyBuild acquihires development studio Demagic Games

    tinyBuild plc (LON:TBLD), a premium video games publisher and developer with global operations, has announced the acquihire of Demagic Games, a development studio with 23 staff[1] currently based in Ukraine and Russia. The Company has been working

    Vertu Motors Plc

    Vertu Motors share buyback programme update

    Vertu Motors plc (LON: VTU) has announced that on 07 April 2022, it purchased 201,999 ordinary shares of 10p each in the Company on the London Stock Exchange, pursuant to the share buyback programme that was announced on 2nd March 2022 as

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer